Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials - PubMed (original) (raw)
Meta-Analysis
. 2007 Apr 18;297(15):1683-96.
doi: 10.1001/jama.297.15.1683.
Affiliations
- PMID: 17440145
- DOI: 10.1001/jama.297.15.1683
Meta-Analysis
Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials
Jeffrey A Bridge et al. JAMA. 2007.
Abstract
Context: The US Food and Drug Administration (FDA) has issued warnings that use of antidepressant medications poses a small but significantly increased risk of suicidal ideation/suicide attempt for children and adolescents.
Objective: To assess the efficacy and risk of reported suicidal ideation/suicide attempt of antidepressants for treatment of pediatric major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and non-OCD anxiety disorders.
Data sources and study selection: PubMed (1988 to July 2006), relevant US and British regulatory agency reports, published abstracts of important scientific meetings (1998-2006), clinical trial registries, and information from authors. Studies were published and unpublished randomized, placebo-controlled, parallel-group trials of second-generation antidepressants (selective serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participants younger than 19 years with MDD, OCD, or non-OCD anxiety disorders.
Data extraction: Information was extracted on study characteristics, efficacy outcomes, and spontaneously reported suicidal ideation/suicide attempt.
Data synthesis: Twenty-seven trials of pediatric MDD (n = 15), OCD (n = 6), and non-OCD anxiety disorders (n = 6) were selected, and risk differences for response and for suicidal ideation/suicide attempt estimated by random-effects methods. Pooled risk differences in rates of primary study-defined measures of responder status significantly favored antidepressants for MDD (11.0%; [95% confidence interval {CI}, 7.1% to 14.9%]), OCD (19.8% [95% CI, 13.0% to 26.6%), and non-OCD anxiety disorders (37.1% [22.5% to 51.7%]), corresponding to a number needed to treat (NNT) of 10 (95% CI, 7 to 15), 6 (4 to 8), and 3 (2 to 5), respectively. While there was increased risk difference of suicidal ideation/suicide attempt across all trials and indications for drug vs placebo (0.7%; 95% CI, 0.1% to 1.3%) (number needed to harm, 143 [95% CI, 77 to 1000]), the pooled risk differences within each indication were not statistically significant: 0.9% (95% CI, -0.1% to 1.9%) for MDD, 0.5% (-1.2% to 2.2%) for OCD, and 0.7% (-0.4% to 1.8%) for non-OCD anxiety disorders. There were no completed suicides. Age-stratified analyses showed that for children younger than 12 years with MDD, only fluoxetine showed benefit over placebo. In MDD trials, efficacy was moderated by age, duration of depression, and number of sites in the treatment trial.
Conclusions: Relative to placebo, antidepressants are efficacious for pediatric MDD, OCD, and non-OCD anxiety disorders, although the effects are strongest in non-OCD anxiety disorders, intermediate in OCD, and more modest in MDD. Benefits of antidepressants appear to be much greater than risks from suicidal ideation/suicide attempt across indications, although comparison of benefit to risk varies as a function of indication, age, chronicity, and study conditions.
Comment in
- Benefits and harms of pediatric antidepressant medications.
Edwards JL, Kirk KK, Midha CK. Edwards JL, et al. JAMA. 2007 Aug 8;298(6):626-7; author reply 627. doi: 10.1001/jama.298.6.626-b. JAMA. 2007. PMID: 17684183 No abstract available. - Benefits and harms of pediatric antidepressant medications.
Waslick B. Waslick B. JAMA. 2007 Aug 8;298(6):626; author reply 627. doi: 10.1001/jama.298.6.626-a. JAMA. 2007. PMID: 17684184 No abstract available. - Review: benefits of antidepressants outweigh risks of suicidal ideation and attempts in children and adolescents.
Hammad TA. Hammad TA. Evid Based Ment Health. 2007 Nov;10(4):108. doi: 10.1136/ebmh.10.4.108. Evid Based Ment Health. 2007. PMID: 17962653 No abstract available.
Similar articles
- Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME. Carpenter DJ, et al. J Clin Psychiatry. 2011 Nov;72(11):1503-14. doi: 10.4088/JCP.08m04927blu. Epub 2011 Feb 22. J Clin Psychiatry. 2011. PMID: 21367354 - Citalopram and suicidality in adult major depression and anxiety disorders.
Pedersen AG. Pedersen AG. Nord J Psychiatry. 2006;60(5):392-9. doi: 10.1080/08039480600937561. Nord J Psychiatry. 2006. PMID: 17038305 - Suicide rates in short-term randomized controlled trials of newer antidepressants.
Hammad TA, Laughren TP, Racoosin JA. Hammad TA, et al. J Clin Psychopharmacol. 2006 Apr;26(2):203-7. doi: 10.1097/01.jcp.0000203198.11453.95. J Clin Psychopharmacol. 2006. PMID: 16633153 - Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment.
Boaden K, Tomlinson A, Cortese S, Cipriani A. Boaden K, et al. Front Psychiatry. 2020 Sep 2;11:717. doi: 10.3389/fpsyt.2020.00717. eCollection 2020. Front Psychiatry. 2020. PMID: 32982805 Free PMC article. - Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders.
Cohen D, Consoli A, Bodeau N, Purper-Ouakil D, Deniau E, Guile JM, Donnelly C. Cohen D, et al. J Child Adolesc Psychopharmacol. 2010 Feb;20(1):39-47. doi: 10.1089/cap.2009.0047. J Child Adolesc Psychopharmacol. 2010. PMID: 20166795 Review.
Cited by
- Adverse effects information in clinical guidelines on pharmacological treatment of depression in children and adolescents: a systematic review.
Westergren T, Narum S, Klemp M. Westergren T, et al. BMJ Open. 2020 Jul 20;10(7):e036412. doi: 10.1136/bmjopen-2019-036412. BMJ Open. 2020. PMID: 32690742 Free PMC article. - The complex role of sleep in adolescent depression.
Clarke G, Harvey AG. Clarke G, et al. Child Adolesc Psychiatr Clin N Am. 2012 Apr;21(2):385-400. doi: 10.1016/j.chc.2012.01.006. Child Adolesc Psychiatr Clin N Am. 2012. PMID: 22537732 Free PMC article. Review. - Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood.
Akyol Ardic U, Ercan ES, Kutlu A, Yuce D, Ipci M, Inci SB. Akyol Ardic U, et al. Child Psychiatry Hum Dev. 2017 Oct;48(5):699-704. doi: 10.1007/s10578-016-0694-8. Child Psychiatry Hum Dev. 2017. PMID: 27812841 - Treatment of puberty trichotillomania with low-dose aripiprazole.
Sasaki T, Iyo M. Sasaki T, et al. Ann Gen Psychiatry. 2015 Jun 17;14:18. doi: 10.1186/s12991-015-0056-0. eCollection 2015. Ann Gen Psychiatry. 2015. PMID: 26089954 Free PMC article. - Antidepressant-induced suicidality: an update.
Reeves RR, Ladner ME. Reeves RR, et al. CNS Neurosci Ther. 2010 Aug;16(4):227-34. doi: 10.1111/j.1755-5949.2010.00160.x. Epub 2010 Apr 16. CNS Neurosci Ther. 2010. PMID: 20553304 Free PMC article. Review.